Steven Targum - Alterity Therapeutics Chief Advisor
| ATHE Stock | USD 1.06 0.01 0.95% |
Insider
Steven Targum is Chief Advisor of Alterity Therapeutics
| Address | 350 Collins Street, Melbourne, VIC, Australia, 3000 |
| Phone | 61 3 9349 4906 |
| Web | https://alteritytherapeutics.com |
Alterity Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.5266) % which means that it has lost $0.5266 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0447) %, meaning that it created substantial loss on money invested by shareholders. Alterity Therapeutics' management efficiency ratios could be used to measure how well Alterity Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 27, 2024, Return On Tangible Assets is expected to decline to -1.04. In addition to that, Return On Capital Employed is expected to decline to -1.49. At present, Alterity Therapeutics' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Fixed Asset Turnover is expected to grow to 22.58, whereas Non Current Assets Total are forecasted to decline to about 177.5 K.Similar Executives
| Showing other executives | INSIDER Age | ||
| James JD | Eliem Therapeutics | 58 | |
| MD BA | Lumos Pharma | 69 | |
| FACC MD | Milestone Pharmaceuticals | 60 | |
| MBA MD | Eliem Therapeutics | 63 | |
| Guy Rousseau | Milestone Pharmaceuticals | N/A | |
| Bradley JD | Lumos Pharma | 45 | |
| BBA CPA | Lumos Pharma | 57 | |
| Jeff Nelson | Milestone Pharmaceuticals | 43 | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| Lori CPA | Lumos Pharma | 40 | |
| David MBA | Seres Therapeutics | 63 | |
| Philippe MBA | Milestone Pharmaceuticals | 62 | |
| Lorenz Muller | Milestone Pharmaceuticals | 60 | |
| Kimberly Sheehan | Milestone Pharmaceuticals | N/A | |
| FACC FAHA | Milestone Pharmaceuticals | 66 | |
| Jeff York | Seres Therapeutics | N/A | |
| Richard Hawkins | Lumos Pharma | 75 | |
| Carl Langren | Lumos Pharma | 69 | |
| Lisa Miller | Lumos Pharma | N/A | |
| Robert MBA | Eliem Therapeutics | 56 | |
| Katherine Taudvin | Scpharmaceuticals | N/A | |
Management Performance
| Return On Equity | -1.04 | ||||
| Return On Asset | -0.53 |
Alterity Therapeutics Leadership Team
Elected by the shareholders, the Alterity Therapeutics' board of directors comprises two types of representatives: Alterity Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alterity. The board's role is to monitor Alterity Therapeutics' management team and ensure that shareholders' interests are well served. Alterity Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alterity Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Cherny, Head Research | ||
| BBus CA, Company Sec | ||
| BSc BSc, CoFounder Chairman | ||
| Kathryn Andrews, Chief Officer | ||
| Steven Targum, Chief Advisor | ||
| CPA BCom, Chief Officer | ||
| Steven MD, Chief Advisor | ||
| BCom BSc, Chief Officer | ||
| Geoffrey BSc, CoFounder Chairman | ||
| David MD, Chief Officer | ||
| Rudolph Tanzi, Chief Board |
Alterity Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alterity Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.04 | ||||
| Return On Asset | -0.53 | ||||
| Operating Margin | (6.13) % | ||||
| Current Valuation | 2.13 M | ||||
| Shares Outstanding | 8.74 M | ||||
| Shares Owned By Institutions | 1.28 % | ||||
| Number Of Shares Shorted | 3.57 K | ||||
| Price To Earning | (4.84) X | ||||
| Price To Book | 1.02 X | ||||
| Price To Sales | 2.55 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Alterity Therapeutics is a strong investment it is important to analyze Alterity Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Alterity Therapeutics' future performance. For an informed investment choice regarding Alterity Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alterity Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For information on how to trade Alterity Stock refer to our How to Trade Alterity Stock guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alterity Therapeutics. If investors know Alterity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alterity Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.84) | Revenue Per Share 0.6 | Quarterly Revenue Growth 0.384 | Return On Assets (0.53) | Return On Equity (1.04) |
The market value of Alterity Therapeutics is measured differently than its book value, which is the value of Alterity that is recorded on the company's balance sheet. Investors also form their own opinion of Alterity Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Alterity Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alterity Therapeutics' market value can be influenced by many factors that don't directly affect Alterity Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alterity Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alterity Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alterity Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.